BCL2 and myelodysplastic syndrome: ABT-737 has already shown its efficacy in vitro on the apoptosis of carcinoma and AML cell lines [14], ex vivo on patient blasts, [15] in vivo on a murine model of lymphoma [16], on a xenograft model of small cell lung cancer [17] and our own mouse model of MRP8[NRASD12/BCL-2] AML post-MDS [9].